ROIV · XBRL financial data

Roivant Sciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ROIV's year ends in late March)

In millions of dollars	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY23Mar 31, 2024	Q1 FY24Jun 30, 2024	Q2 FY24Sep 30, 2024	Q3 FY24Dec 31, 2024	Q4 FY24Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025	Q3 FY25Dec 31, 2025	Q4 FY25Mar 31, 2026	Q1 FY26Jun 30, 2026
Revenue from contracts with customers	37	37	29*	55	4	9	8*	2	2	2	3*	1
Research and development	132	124	121*	133	143	142	145*	153	165	165	199*	202
Selling, general and administrative	164	197	170*	149	—	—	—	—	—	—	—	—
General and administrative	89	128	108*	100	203	142	147*	134	143	175	158*	166
Total operating expenses	314	325	295*	286	346	283	293*	287	308	341	358*	368
Operating income (loss)	(276)	5,061	(266)*	(120)	(342)	(274)	(285)*	(285)	(306)	(339)	415*	(366)
Interest income	—	—	year only	—	70	62	55*	48	45	43	41*	37
Interest expense	9	9	7*	13	—	—	—	—	—	—	—	—
Other income (expense)	(6)	35	(39)*	(2)	(1)	(3)	(3)*	(11)	(6)	8	13*	(2)
Income tax expense (benefit)	4	26	(9)*	13	12	(26)	49*	5	7	23	98*	(4)
Net income (loss)	(304)	5,096	(151)*	95	(230)	169	(206)*	(223)	(114)	(266)	303*	(190)
Earnings per share, basic USD per share	(0.40)	6.37	(0.19)*	0.13	(0.31)	0.23	(0.29)*	(0.33)	(0.17)	(0.38)	0.42*	(0.26)
Earnings per share, diluted USD per share	(0.40)	6.03	(0.16)*	0.12	(0.31)	0.23	(0.31)*	(0.33)	(0.17)	(0.38)	—	(0.26)
Weighted average shares, basic millions of shares	770	801	803*	736	735	723	707*	680	681	697	718*	721
Weighted average shares, diluted millions of shares	770	844	951*	782	735	723	661*	680	681	697	718*	721

Fiscal quarters (ROIV's year ends in late March)

In millions of dollars	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY23Mar 31, 2024	Q1 FY24Jun 30, 2024	Q2 FY24Sep 30, 2024	Q3 FY24Dec 31, 2024	Q4 FY24Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025	Q3 FY25Dec 31, 2025	Q4 FY25Mar 31, 2026	Q1 FY26Jun 30, 2026
Cash and cash equivalents	1,408	6,671	6,536	5,679	1,959	1,991	2,715	1,238	1,237	1,478	1,419	1,248
Marketable securities	—	—	0	—	3,428	3,156	2,171	3,265	3,149	3,052	2,873	2,594
Inventory	5	5	35	34	—	—	—	—	—	—	—	—
Total current assets	1,552	6,807	6,732	6,001	5,801	5,364	5,000	4,616	4,512	4,660	5,167	4,742
Property and equipment, net	24	22	19	18	14	14	12	15	26	13	12	11
Right-of-use asset	49	47	47	45	43	91	89	87	85	84	80	79
Total assets	2,066	7,313	7,222	6,496	6,206	5,792	5,437	5,033	5,063	5,225	5,709	5,306
Accounts payable	44	35	53	28	25	24	24	12	15	13	18	25
Accrued liabilities	153	122	176	138	111	104	114	89	108	118	206	169
Current portion of long-term debt	49	46	12	12	—	—	—	—	—	—	—	—
Total current liabilities	266	245	267	215	556	141	149	114	134	152	281	284
Lease liability, non-current	49	47	47	46	43	90	90	90	90	99	96	95
Total liabilities	740	728	774	601	626	256	250	217	257	251	416	385
Retained earnings (accumulated deficit)	(4,369)	727	576	671	396	460	116	(316)	(429)	(695)	(502)	(900)
Total stockholders' equity	949	6,090	5,969	5,435	5,153	5,189	4,688	4,346	4,362	4,269	4,527	4,231
Total liabilities and equity	2,066	7,313	7,222	6,496	6,206	5,792	5,437	5,033	5,063	5,225	5,709	5,306
Common shares outstanding (cover page) millions of shares	804	806	739	740	728	714	680	683	695	716	719	722

Fiscal quarters (ROIV's year ends in late March)

In millions of dollars	Q2 FY23Sep 30, 2023	Q3 FY23Dec 31, 2023	Q4 FY23Mar 31, 2024	Q1 FY24Jun 30, 2024	Q2 FY24Sep 30, 2024	Q3 FY24Dec 31, 2024	Q4 FY24Mar 31, 2025	Q1 FY25Jun 30, 2025	Q2 FY25Sep 30, 2025	Q3 FY25Dec 31, 2025	Q4 FY25Mar 31, 2026	Q1 FY26Jun 30, 2026
Net income (loss)	(304)	5,096	(151)*	95	(230)	169	(206)*	(223)	(114)	(266)	303*	(190)
Stock-based compensation	49*	54*	47*	50	72*	84*	83*	82	82*	105*	77*	83
Depreciation and amortization	6*	5*	5*	5	5*	3*	1*	1	1*	1*	1*	1
Net cash from operating activities	(196)*	(210)*	(108)*	(193)	(267)*	(207)*	(173)*	(204)	(186)*	(196)*	(164)*	(271)
Purchases of property and equipment	0*	0*	0*	1	1*	2*	1*	4	8*	(5)*	1*	0
Net cash from investing activities	(36)*	5,233*	7*	(1)	(3,294)*	454*	1,074*	(1,086)	120*	109*	173*	281
Proceeds from issuing common stock	—	0*	0*	—	—	0*	0*	—	—	—	year only	—
Share repurchases	0*	0*	0*	648	106*	243*	295*	208	0*	0*	—	207
Net cash from financing activities	208*	237*	(33)*	(661)	(109)*	(273)*	(177)*	(188)	63*	328*	(69)*	(182)
Net change in cash	(26)*	5,262*	(135)*	(857)	(3,664)*	(27)*	724*	(1,477)	(1)*	242*	(58)*	(170)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
United Therapeutics	1,803	783	314*	42.9M	—	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.